Content about Strides Arcolab

December 5, 2013

Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

September 3, 2013

Indian regulators have approved a deal from Mylan to buy the injectables business of Strides Arcolab, Mylan said Tuesday.

PITTSBURGH — Indian regulators have approved a deal from Mylan to buy the injectables business of Strides Arcolab, Mylan said Tuesday.

Following the approval of Agila by India's Foreign Investment Promotion Board, Mylan also received approval from the Cabinet Committee on Economic Affairs. The deal is expected to close in fourth quarter 2013. Mylan announced its plan to buy Agila for $1.6 billion in February 2013.

February 28, 2013

Mylan has bought a manufacturer of generic injectables for $1.6 billion, the company said.

PITTSBURGH — Mylan has bought a manufacturer of generic injectables for $1.6 billion, the company said.

Mylan announced the acquisition of Bangalore, India-based Agila from Strides Arcolab, which Mylan said would allow it to strengthen its injectables business and enter new markets around the world.

October 3, 2011

The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

SCHAUMBURG, Ill. — The Food and Drug Administration has approved a generic antibiotic made by Sagent Pharmaceuticals, Sagent said.

The drug maker announced the approval of clindamycin injection, which the company said was the 12th product approved under its joint venture with Strides Arcolab, under which Strides is responsible for developing and supplying injectable products that Sagent markets in the United States.

The market for injectable clindamycin this year is about $65 million, according to IMS Health.

July 29, 2011

The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

BANGALORE, India — The Food and Drug Administration has approved a generic drug for diabetes made by Indian generic drug maker Strides Arcolab.

The FDA approved acarbose tablets in the 25-mg, 50-mg and 100-mg strengths. The drug is a niche drug used to treat Type 2 diabetes, Strides said.

Acarbose tablets have sales of about $21 million, according to IMS Health.